The novel K V 7 channel activator URO-K10 exerts enhanced pulmonary vascular effects independent of the KCNE4 regulatory subunit.

Autor: Villegas-Esguevillas M; Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain., Cho S; Department of Physiology, College of Medicine, Seoul National University, Seoul, South Korea., Vera-Zambrano A; Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain., Kwon JW; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain., Barreira B; Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain., Telli G; Department of Pharmacology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey., Navarro-Dorado J; Departamento de Fisiología, Facultad de Farmacia, Universidad Complutense, Madrid, Spain., Morales-Cano D; Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain., de Olaiz B; Department of Thoracic Surgery, Hospital Universitario de Getafe, Getafe, Spain., Moreno L; Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain., Greenwood I; Vascular Biology Research Centre, Institute of Molecular and Clinical Sciences, St George's University of London, United Kingdom., Pérez-Vizcaíno F; Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain., Kim SJ; Department of Physiology, College of Medicine, Seoul National University, Seoul, South Korea., Climent B; Departamento de Fisiología, Facultad de Farmacia, Universidad Complutense, Madrid, Spain. Electronic address: bcliment@ucm.es., Cogolludo A; Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Aug; Vol. 164, pp. 114952. Date of Electronic Publication: 2023 Jun 07.
DOI: 10.1016/j.biopha.2023.114952
Abstrakt: K V 7 channels exert a pivotal role regulating vascular tone in several vascular beds. In this context, K V 7 channel agonists represent an attractive strategy for the treatment of pulmonary arterial hypertension (PAH). Therefore, in this study, we have explored the pulmonary vascular effects of the novel K V 7 channel agonist URO-K10. Consequently, the vasodilator and electrophysiological effects of URO-K10 were tested in rat and human pulmonary arteries (PA) and PA smooth muscle cells (PASMC) using myography and patch-clamp techniques. Protein expression was also determined by Western blot. Morpholino-induced knockdown of KCNE4 was assessed in isolated PA. PASMC proliferation was measured by BrdU incorporation assay. In summary, our data show that URO-K10 is a more effective relaxant of PA than the classical K V 7 activators retigabine and flupirtine. URO-K10 enhanced K V currents in PASMC and its electrophysiological and relaxant effects were inhibited by the K V 7 channel blocker XE991. The effects of URO-K10 were confirmed in human PA. URO-K10 also exhibited antiproliferative effects in human PASMC. Unlike retigabine and flupirtine, URO-K10-induced pulmonary vasodilation was not affected by morpholino-induced knockdown of the KCNE4 regulatory subunit. Noteworthy, the pulmonary vasodilator efficacy of this compound was considerably increased under conditions mimicking the ionic remodelling (as an in vitro model of PAH) and in PA from monocrotaline-induced pulmonary hypertensive rats. Taking all together, URO-K10 behaves as a KCNE4-independent K V 7 channel activator with much increased pulmonary vascular effects compared to classical K V 7 channel activators. Our study identifies a promising new drug in the context of PAH.
Competing Interests: Declaration of Competing Interest None. The authors have reported that they have no relationships with industry relevant to the contents of this paper to disclose. The funders played no role in the study design; nor in the collection, analyses, interpretation of data, nor in the writing of the manuscript.
(Copyright © 2023. Published by Elsevier Masson SAS.)
Databáze: MEDLINE
Externí odkaz: